TSBX turnstonebio.com: Enterprise Value to EBITDA Ratio
The price action of Turnstone Biologics (TSBX) based on the EV/EBITDA metric is . Turnstone Biologics is implementing an innovative method of modifying autologous lymphocytes to destroy neoplasms. However, international conflicts may hinder the procurement of reagents and the protection of intellectual property rights. While the company currently generates no revenue, future income will be based on exclusive patents for the treatment of solid tumors.
Summary analytical data breakdowns for turnstonebio.com (TSBX)
- stock price and consensus target price:
- company stock capitalization data:
- business book valuation details:
- debt and solvency information:
Debt to Equity Turnstone Biologics|TSBX - Long-Term Debt to Equity Ratio|Short-Term Debt to Equity Ratio Turnstone Biologics Corp.|TSBX - Company Aggregate Debts|Debt to Book Capitalization Ratio Turnstone Biologics Corp.|TSBX - Company Long-Term Indebtedness|Company Short-Term Debt Turnstone Biologics|Quick Liquidity Indicator turnstonebio.com
- financial results and valuation multiples details:
TSBX - Annual Net Income|Future Profit Turnstone Biologics|TSBX - Market Price to Net Income Ratio|Forward P/E Multiple Turnstone Biologics Corp.|TSBX - Growth-Adjusted Payback Ratio|EV/EBITDA Multiple Turnstone Biologics Corp.|TSBX - Profit before interest, taxes and amortization|Earnings per share for the last twelve months Turnstone Biologics|TSBX - Earnings per share for the trailing year|Quarterly EPS earnings growth turnstonebio.com|TSBX - Earnings growth in current year|Net earnings per share growth forecast for next year Turnstone Biologics
Fundamental company analysis:TSBX (Turnstone Biologics Corporation)
The EV/EBITDA multiple assesses the total value of a business relative to its operating profit before interest and taxes. The trend in the EV/EBITDA multiple for Turnstone Biologics (TSBX) reflects a market revaluation of assets compared to generated cash flow. For Turnstone Biologics (TSBX), this metric is critical, as the absence of regular revenue and dependence on clinical trial outcomes make the enterprise value sensitive to debt load.
Competitor analysis for Turnstone Biologics
ImmunityBio Corp - Enterprise Value to EBITDA Ratio|Immunocore Corp (IMCR) - Company Value to EBITDA|JANX: Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation RCUS (arcusbio.com)|ZYME: EV/EBITDA Multiple|TNGX - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Iovance|Enterprise Value to EBITDA Ratio Immatics Biotechnologies (IMTX)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Xencor, Inc. (XNCR)|Enterprise Value to EBITDA Ratio compasstherapeutics.com CMPX|Replimune - Enterprise Value to EBITDA Ratio|EV/EBITDA Multiple Lyell LYEL|IPHA - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|PYXS (Pyxis Oncology, Inc.) - Enterprise Value to Operating Income Before Depreciation|cgen.com (CGEN) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA iobiotech.com (IOBT)|Enterprise Value to EBITDA Ratio STRO|INKT - Enterprise Value to EBITDA Multiple|Enterprise Value to EBITDA Ratio HOWL (Werewolf Therapeutics)|Enterprise Value to Operating Income Before Depreciation Ratio IMMX|EV/EBITDA Multiple ALXO (ALX Oncology)|Business Value to Operating Income Before Depreciation CUE|PDS Biotechnology Corp - EV/EBITDA Multiple|Company Value to EBITDA Sonnet BioTherapeutics|MAIA Biotechnology Inc (MAIA) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Liminatus - Business Value to Operating Income Before Depreciation|LVTX (LAVA Therapeutics NV) - EV/EBITDA Multiple|EV/EBITDA Multiple nextcure.com|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Leap Therapeutics, Inc. (LPTX)|INTS: Company Value to Operating Income Before Depreciation Ratio|Sensei Biotherapeutics, Inc. - Enterprise Value to EBITDA Ratio|Theriva Corp (TOVX) - Company Value to EBITDA|GRTS: Enterprise Value to EBITDA Ratio|kinetabio.com - Enterprise Value to Operating Income Before Depreciation Ratio|NEXI (NexImmune) - Enterprise Value to EBITDA Ratio|Vaccinex Inc. (VCNX) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Harpoon Tx
